By Suresh K. Daniel, PhD and Elon Gilbert, PhD
Volume 9, Issue 2 (Winter 2010/2011)
J&J’s recent recall of Motrin and other pharmaceutical products is more than a cautionary tale in crisis management. It raises a very important question: Why do companies hesitate to address known risks (in this case the QC problems at a specific manufacturing facility)? As Douglas McIntyre, editor of 24/7 Wall Street, stated in a recent posting, “Acting early would probably be harmless at worst and might be critical to success.” However, he admits that few companies have gotten the message. But why?…
Citation: Daniel SK, Gilbert E. Perpetuating Risk: Why Are Companies Slow To Address Potentially Serious Hazards?. BioProcess J, 2011; 9(2): 4-5. https://dx.doi.org/10.12665/J92.Daniel
Posted online February 9, 2011